Cash cravings

BioCentury's 13th annual European Iceberg survey foresees record financing demand, driven on the public side by higher burn rates and the number of companies joining the group via IPOs, and on the private side by the addition of companies meeting the survey criteria.

The survey aims to identify the underlying funding demand by biotechs in Europe, plus Israel, over the next three years. It arrives at this aggregate figure by polling private companies and extrapolating capital needs from the financial reports of public companies. The survey only includes companies that have reached the clinic or the market, and profitable publicly traded biotechs are excluded...